What is known about the safety of Cytotect CP Biotest (CMVIG) during pregnancy?

Cytotect CP Biotest (CMVIG) safety during pregnancy has not been established in controlled clinical trials, so it should be given cautiously; IVIg crosses the placenta increasingly in the third trimester, although immunoglobulin experience and CMVIG data suggest no harmful effects on pregnancy, the foetus or neonate are expected.